Law360, Washington (May 5, 2017, 7:38 PM EDT) -- U.S. Food and Drug Administration leaders, as well as experts from Big Pharma and BigLaw, took the stage at a major annual conference and shared wide-ranging perspectives on the agency's likely priorities and policies under the Trump administration.
The conference drew hundreds of attorneys on Thursday and Friday to the Ronald Reagan Building and International Trade Center in Washington, D.C.
Here are four key takeaways from Thursday's sessions at the Food and Drug Law Institute's annual gathering.
FDA Will Stay 'Fresh,' Ostroff Says
Stephen Ostroff, the FDA's acting commissioner, delivered a keynote address that came across at times like a pep...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!